Omnicell (OMCL) to Post Quarterly Earnings on Thursday

Posted by on Jul 29th, 2026

Omnicell (NASDAQ:OMCL – Get Free Report) is anticipated to post its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Omnicell to announce earnings of $0.48 per share and revenue of $310.2130 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

Omnicell (NASDAQ:OMCL – Get Free Report) last issued its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The company had revenue of $309.88 million during the quarter, compared to analysts’ expectations of $304.02 million. During the same period in the prior year, the business earned $0.26 EPS. The firm’s quarterly revenue was up 14.9% on a year-over-year basis. On average, analysts expect Omnicell to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Omnicell Stock Up 3.8%

Shares of OMCL opened at $43.05 on Wednesday. Omnicell has a 52-week low of $28.51 and a 52-week high of $55.00. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. The stock has a fifty day simple moving average of $42.35 and a two-hundred day simple moving average of $41.30. The company has a market capitalization of $1.96 billion, a PE ratio of 97.84, a price-to-earnings-growth ratio of 1.07 and a beta of 0.96.

Insider Transactions at Omnicell

In other Omnicell news, EVP Nnamdi Njoku sold 3,090 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the transaction, the executive vice president owned 154,785 shares of the company’s stock, valued at $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the transaction, the executive vice president directly owned 112,783 shares in the company, valued at $4,874,481.26. The trade was a 4.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Omnicell

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Cerity Partners LLC lifted its holdings in shares of Omnicell by 4.9% in the 4th quarter. Cerity Partners LLC now owns 7,613 shares of the company’s stock worth $345,000 after acquiring an additional 354 shares during the last quarter. Thrivent Financial for Lutherans raised its position in Omnicell by 1.2% in the second quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock valued at $1,013,000 after purchasing an additional 424 shares during the period. Legal & General Group Plc raised its position in Omnicell by 0.3% in the third quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock valued at $4,823,000 after purchasing an additional 448 shares during the period. California State Teachers Retirement System lifted its stake in Omnicell by 1.7% during the second quarter. California State Teachers Retirement System now owns 42,552 shares of the company’s stock worth $1,251,000 after purchasing an additional 692 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Omnicell during the second quarter worth $26,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on OMCL shares. Weiss Ratings raised shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Zacks Research lowered shares of Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. KeyCorp increased their price target on shares of Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. Finally, Craig Hallum restated a “buy” rating and set a $55.00 price target on shares of Omnicell in a report on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $59.86.

Check Out Our Latest Stock Analysis on OMCL

About Omnicell

(Get Free Report)

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

Featured Stories

Earnings History for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.